The University of Kansas Heartland Institute for Clinical and Translational Research (HICTR) was established in 2007 in response to the national CTSA initiative. The vision of the HICTR is to improve the health of Kansans by creating a novel and transformative translational research enterprise from bench to bedside to community. Particular strengths of our HICTR program are an entrepreneurial drug and device discovery and development program and a well-developed and highly accomplished community-based research program.
The specific aims of the HICTR are to: 1) create a new academic home with innovative training programs for clinical and translational Investigators;2) provide an enhanced coordinated translational research infrastructure;and 3) actively engage the community in developing, testing, and disseminating research, by capitalizing on and expanding existing networks, to improve the health of all Kansans?especially those in rural, underserved and other target communities. The proposed infrastructure and educational programs of the HICTR will address the challenges facing clinical and translational investigators by enhancing and integrating existing resources for easier access, developing new innovative resources, and capitalizing on resources residing in research centers across the university?including our KINBRE and five COBRE grants~and our HICTR network institutions. In support of our aims, we have marshaled an impressive array of institutional, corporate, and community resources in planning, developing, and establishing the HICTR. The HICTR will provide new infrastructure and training and educational programs to support investigators'clinical and translational research?taking laboratory discoveries to first trials in humans (Tl research) and moving research through to studies on dissemination and implementation of research findings to practice (T2 research). With extraordinary institutional and community support, we already have made tremendous progress. Funding from the CTSA program will allow the University of Kansas'HICTR the opportunity to fully realize its potential not only for our region, but also to contribute to the national CTSA Consortium.
The University of Kansas Heartland Institute for Clinical and Translational Research is an academic home for clinical and translational research, providing support to scientists and involving the community, so that discoveries and research findings wi|l be brought more rapidly to the point of care, thus improving the health of all Kansans.
|Searl, Jeff; Knollhoff, Stephanie; Barohn, Richard J (2017) Lingual-Alveolar Contact Pressure During Speech in Amyotrophic Lateral Sclerosis: Preliminary Findings. J Speech Lang Hear Res 60:810-825|
|Woolbright, Benjamin L; Ding, Wen-Xing; Jaeschke, Hartmut (2017) Caspase inhibitors for the treatment of liver disease: friend or foe? Expert Rev Gastroenterol Hepatol 11:397-399|
|Clausen, Ashley N; Billinger, Sandra A; Sisante, Jason-Flor V et al. (2017) Preliminary Evidence for the Impact of Combat Experiences on Gray Matter Volume of the Posterior Insula. Front Psychol 8:2151|
|Britt, Nicholas S; Patel, Nimish; Shireman, Theresa I et al. (2017) Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia. J Antimicrob Chemother 72:535-542|
|Nollen, Nicole L; Mayo, Matthew S; Clark, Lauren et al. (2017) Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products. Drug Alcohol Depend 179:330-336|
|Kandel, Sylvie E; Han, Lyrialle W; Mao, Qingcheng et al. (2017) Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos 45:1266-1275|
|Brosnahan, Godela; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Curr Hypertens Rev :|
|Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500|
|Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2017) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int :|
|D?Silva, Linda J; Staecker, Hinrich; Lin, James et al. (2017) Otolith Dysfunction in Persons With Both Diabetes and Benign Paroxysmal Positional Vertigo. Otol Neurotol 38:379-385|
Showing the most recent 10 out of 245 publications